[Federal Register Volume 75, Number 56 (Wednesday, March 24, 2010)]
[Notices]
[Page 14190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-6415]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 4, 2009, Sigma 
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, 
Massachusetts 01760-2447, made application by renewal to the Drug 
Enforcement Administration (DEA) as a bulk manufacturer of the basic 
classes of controlled substances in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
Aminorex (1585)............................  I
Alpha-ethyltryptamine (7249)...............  I
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (7370)...............  I
------------------------------------------------------------------------


------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (MDMA)     I
 (7405).
Psilocybin (7437)..........................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).  I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP)  I
 (7470).
N-Benzylpiperazine (BZP) (7493)............  I
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Nabilone (7379)............................  II
1-Phenylcyclohexylamine (7460).............  II
Phencyclidine (7471).......................  II
Cocaine (9041..............................  II
Codeine (9050).............................  II
Diprenorphine (9058).......................  II
Ecgonine (9180)............................  II
------------------------------------------------------------------------


------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Levomethorphan (9210)......................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Metazocine (9240)..........................  II
Methadone (9250)...........................  II
Morphine (9300)............................
II Thebaine (9333).........................  II
Levo-alphacetylmethadol (9648).............  II
Remifentanil (9739)........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture reference standards.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such a substance, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA 22152; and must be filed no later 
than May 24, 2010.

    Dated: March 16, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-6415 Filed 3-23-10; 8:45 am]
BILLING CODE 4410-09-P